ECO2025 (32nd European Congress on Obesity)

Conference Name: ECO 2025 (32nd European Congress on Obesity)

Time: May 11-14, 2025

Location: Malaga, Spain

Axcelead will be attending ECO 2025 in Malaga, Spain. Our scientist, Kosuke Hitaka, will be presenting a poster at the conference. We look forward to meeting you there!

Poster Presentation

Title:Comparison of anti-obese effects on GLP-1 analogue peptides, Semaglutide, Tirzepatide and Retatrutide using MC4R deficient obesity model mice

Presenter: Kosuke Hitaka

Date&Time: May 13th, Tuesday, 18:00-18:45

Poster Number:PO4.142

Abstract:
In 2024, semaglutide, a GLP-1 agonist, was launched as a treatment for obesity, making headlines. In recent years, clinical trial results of Tirzepatide and Retatrutide have been reported, and their high anti-obesity effects are expected to improve the quality of life of patients with obesity. On the other hand, there are no reports of non-clinical studies evaluating the effects of these GLP-1 agonists simultaneously. Therefore, in this study, we simultaneously tested semaglutide, tirzepatide, and retatrutide in MC4R KO mice and compared their effects. As a result, it was confirmed that Tirzepatide showed a higher weight loss effect than Semaglutide. The results also suggest that while both GLP-1 agonists have a high anti-obesity effect, they also decrease muscle mass. This result may suggest that the muscle loss effect is a common effect of GLP-1 agonists. We hope that the results of this study will contribute to the development of drug discovery research in the anti-obesity field.

Axcelead DDP’s Solutions:
Well-known obesity models, such as Diet Induced Obesity (DIO) mice, db/db mice, and ob/ob mice, are widely used in research and each has distinct characteristics that make them useful for studying obesity. However, DIO mice are time-consuming to create and db/db and ob/ob mice are associated with diabetes mellitus. MC4R-deficient mouse models, on the other hand, exhibit overeating and become obese early in life but are less likely to develop hyperglycemia. Therefore, MC4R[1]deficient mice are highly valuable for anti-obesity drug discovery research. At Axcelead DDP, we offer comprehensive anti-obesity evaluations using various instruments, including EchoMRI, the Oxymax system, and X-ray CT. These measurement systems are extremely effective not only for evaluating drug efficacy but also investigating for MOA analysis and compound characterization in obesity-related drug discovery research. By combing these technologies with various obesity models, we provide broad support for obesity research.
If you are facing challenges in animal evaluation, MOA analysis, or compound characterization in the obesity research field, please feel free to contact us.